Fig. 1From: Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysisCumulative incidence of the composite of total MACE or non-CV deaths (a) and the composite of total expanded MACE or non-CV deaths (b) in the dulaglutide group (blue line) and the placebo group (red line) during the follow-up. The hazard ratios (HR) are from the proportional means modelBack to article page